Dermatology

Approval has been granted by the FDA for lebrikizumab-lbkz in treating moderate to severe atopic dermatitis in patients aged 12 and older.

Gaps in dermatology education have been spotlighted in preclinical medical students.

The UNCOVER-3 trial is a recent study that has demonstrated that ixekizumab, a biologic treatment for moderate-to-severe plaque psoriasis, is effective in managing psoriasis across challenging body areas including the scalp, face, palmoplantar surfaces, or nails.

Research suggests that Alcaligenes faecalis, a bacterium found in many chronic wounds, can aid in healing difficult-to-treat wounds, especially in people with diabetes.

Results from an ongoing study have demonstrated a high burden of arthritis symptoms in patients with psoriasis.

A study has explored the relationship between psoriasis and COPD to determine whether psoriasis patients are at increased risk for developing COPD.